Hausdorf G
German Heart Center Berlin.
Eur J Anaesthesiol Suppl. 1993;8:25-30.
In a controlled study of newborns with refractory low-output states (n = 16), a bolus dose of enoximone, 1 mg kg-1min-1, produced a dramatic haemodynamic improvement in 12 of 16 patients ('responders'). Of these 12, 9 survived. All 'non-responders' died subsequently. Enoximone resulted in reduced filling pressures (P < 0.005) and improved cardiac index (before enoximone, 0.96 litres min-1 m-2; after enoximone, 3.05 litres min-1 m-2; P < 0.001). To assess the routine use of enoximone in paediatric surgical patients, enoximone was administered post-operatively in 84 children in addition to standard therapy during 1991-92. Clinical improvement was noted in 58 of 84 patients (69%) and no significant side-effects were observed. It is concluded that enoximone provides a safe and effective pharmacological approach for the management of cardiac low-output states in children.
在一项针对难治性低心排血量状态新生儿（n = 16）的对照研究中，给予单次剂量依诺昔酮，1毫克/千克/分钟，16例患者中有12例（“反应者”）出现显著的血流动力学改善。在这12例中，9例存活。所有“无反应者”随后均死亡。依诺昔酮导致充盈压降低（P < 0.005），心脏指数改善（依诺昔酮治疗前为0.96升/分钟/平方米；依诺昔酮治疗后为3.05升/分钟/平方米；P < 0.001）。为评估依诺昔酮在小儿外科患者中的常规应用，1991年至1992年期间，除标准治疗外，对84例儿童术后给予依诺昔酮。84例患者中有58例（69%）出现临床改善，未观察到明显副作用。得出结论，依诺昔酮为治疗儿童心脏低心排血量状态提供了一种安全有效的药理学方法。
